Successful pregnancy outcome of nonimmune hydrops fetalis due to parvovirus B19

1. Cossart Y.E., Field A.M., Cant B., Widdows D. Parvovirus-like particles in human sera. Lancet 1975; 1:72–73. doi: 10.1016/s0140-6736(75)91074-0
2. Anderson M.J., Jones S.E., Fisher-Hoch S.P., Lewis E., Hall S.M., Bartlett C.L., et al. Human parvovirus, the cause of erythema infectiosum (fifth disease). Lancet. 1983; 1:1378.
3. Mossong J. Parvovirus B19 infection in five European countries: seroepidemiology, force of infection and maternal risk of infection. J Epidemiol Infect. 2008; 136:1059–68. doi: 10.1017/S0950268807009661
4. de Jong E.P., Walther F.J., Kroes A.C., Oepkes D. Parvovirus B19 infection in pregnancy: new insights and management. Prenat Diagn. 2011; 31: 419–25. doi: 10.1002/pd.2714.
5. Dijkmans A.C., de Jong E.P., Dijkmans B.A., Lopriore E., Vossen A., Walther F.J., et al. Parvovirus B19 in pregnancy: prenatal diagnosis and management of fetal complications. Curr Opin Obstet Gynecol. 2012; 24: 95–101. doi: 10.1097/GCO.0b013e3283505a9d.
6. Anderson L.J. Role of parvovirus B19 in human disease. Pediatr Infect Dis J. 1987; 6: 711–8. doi: 10.1097/00006454-198708000-00003
7. Markenson G.R., Yancey M.K. Parvovirus B19 infections in pregnancy. Semin Perinatol. 1998; 22: 309–17. doi: 10.1016/s0146-0005(98)80019-0
8. Lamont R.F., Sobel J.D., Vaisbuch E., Kusanovic J.P., Mazaki-Tovi S., Kim S.K. et. al. Parvovirus B19 infection in human pregnancy. BJOG. 2011; 118: 175–86. doi: 10.1111/j.1471-0528.2010.02749.x.
9. Valeur-Jensen A.K., Pedersen C.B., Westergaard T., Jensen I.P., Lebech M., Andersen P.K., et al. Risk factors for parvovirus B19 infection in pregnancy. JAMA. 1999; 281: 1099–1105. doi:10.1001/jama.281.12.1099
10. Nunoue T., Kusuhara K., Hara T. Human fetal infection with parvovirus B19: maternal infection time in gestation, viral persistence and fetal prognosis. Pediatr Infect Dis J. 2002; 21:1133–6. doi: 10.1097/00006454-200212000-00009
11. Васильев В.В., Мурина Е.А., Сидоренко С.В., Мукомолова А.Л. Парвовирусная (B19V) инфекция у беременных и детей раннего возраста. Журнал инфектологии. 2011; 34: 26–33. [Vasiliev V.V., Murina E.A., Sidorenko S.V., Mukomolova A.L. Parvovirus (B19V) infection in pregnant women and young children. Journal of Infectology. 2011; 34: 26–33. (in Russian)].eLIBRARY ID: 17707424
12. Reid D.M., Reid T.M., Brown T., Rennie J.A., Eastmond C.J. Human parvovirus-associated arthritis: a clinical and laboratory description. Lancet. 1985; 1: 422–5. doi: 10.1016/s0140-6736(85)91146-8
13. Servant-Delmas. Advances in human B19 erythrovirus biology. J Virol. 2010; 9658–65. doi: 10.1128/JVI.00684-10.
14. Jones M.S. New DNA viruses identified in patients with acute viral infection syndrome. J. Virol. 2005; 79: 8230–6. doi: 10.1128/JVI.79.13.8230-8236.2005
15. Malm C., Fridell E., Jansson K. Heart failure after parvovirus B19 infection. Lancet. 1993; 341:1408–9. doi: 10.1016/0140-6736(93)90973-k
16. Leduc L.; SOGC Maternal-Fetal Medicine Committee. Stillbirth and bereavement: guidelines for stillbirth investigation. SOGC Clinical Practice Guidelines, No. 178, 2006. J Obstet Gynaecol Can. 2006; 28: 540–52.doi: 10.1016/S1701-2163(16)32172-7
17. Watt A.P., Brown M., Pathiraja M., Anbazhagan A., Coyle P.V. The lack of routine surveillance of parvovirus B19 infection in pregnancy prevents an accurate understanding of this regular cause of fetal loss and the risks posed by occupational exposure. J Med Microbiol. 2013; 62(Pt 1): 86–92. doi: 10.1099/jmm.0.046714-0.
18. Harger J.H., Adler S.P., Koch W.C., Harger G.F. Prospective evaluation of 618 pregnant women exposed to parvovirus B19: risks and symptoms. Obstet Gynecol. 1998; 91: 413–20. doi: 10.1016/s0029-7844(97)00701-1
19. Simms R.A., Liebling R.E., Patel R.R., Denbow M.L., Abdel-Fattah S.A., Soothill P.W. et al. Management and outcome of pregnancies with parvovirus B19 infection over seven years in a tertiary fetal medicine unit. Fetal Diagn Ther. 2009; 25: 373–8. doi: 10.1159/000236149.
20. Козлов П.В., Кузнецов П.А., Леонова Е.И., Константинова К.И. Неиммунная водянка плода. Современный взгляд на проблемы этиологии, патогенеза и перинатального исхода. Проблемы репродукции. 2014; 83–7. [Kozlov P.V., Kuznetsov P.A., Leonova E.I., Konstantinova K.I. Non immune hydrops fetalis. A modern review of the problems of etiology, pathogenesis and perinatal outcome. Reproduction problems. 2014; 83–7.(in Russian)].
21. Crane J., St. John’s N.L., Mundle W., Windsor O.N., Boucoiran I., Vancouver B.C. Parvovirus B19 Infection in Pregnancy. J Obstet Gynaecol Can. 2014; 36(12):1107–16. http://dx.doi.org/10.1016/S1701-2163(15)30390-X
22. Колобов А.В., Карев В.Е., Воробцова И.Н., Орел В.И. Неиммунный отек плода при внутриутробной инфекции. Журнал инфектологии. 2013; 109–112. [Kolobov A.V., Karev V.E., Vorobtsova I.N., Orel V.I. Non immune hydrops fetalis with intrauterine infection. Journal of Infectology. 2013; 109-112. (in Russian)].
23. Enders M., Schalasta G., Baisch C., Weidner A., Pukkila L., Kaikkonen L. et al. Human parvovirus B19 infection during pregnancy—value of modern molecular and serological diagnostics. J Clin Virol. 2006; 35: 400–6. doi: 10.1016/j.jcv.2005.11.002
24. Désilets V., Sherbrooke Q.C., De Bie I., et al. No. 363-Investigation and Management of Non-immune Fetal Hydrops. J Obstet Gynecol Can. 2018; 40(8):1077–90. doi: 10.1016 / j.jogc.2017.12.011
25. Mary E.N., Suneet P.C., Jodi S.D. Society for Maternal-Fetal Medicine (SMFM) Clinical Guideline#7:nonimmune hydrops fetalis. Am J Obstet Gynecol. 2015. http://dx.doi.org/10.1016/j.ajog.2014.12.018
26. Fairley C.K., Smoleniec J.S., Caul O.E., Miller E. Observational study of effect of intrauterine transfusions on outcome of fetal hydrops after parvovirus B19 infection. Lancet. 1995; 346:1335–7. doi: 10.1016/s0140-6736(95)92346-2
27. von Kaisenberg C.S., Jonat W. Fetal parvovirus B19 infection. Ultrasound Obstet Gynecol. 2001; 18: 280–8. doi: 10.1046/j.1469-0705.2001.00471.x
28. Nigro G., Adler S.P., La Torre R., Best A.M. Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J. Med. 2005; 353: 1350–62. doi: 10.1056/NEJMoa043337
29. Matsuda H., Sakaguchi K., Shibasaki T., Takahashi H., Kawakami Y., Furuya K. Intrauterine therapy for parvovirus B19 infected symptomatic fetus using B19 IgG-rich high titer gammaglobulin. J Perinat Med. 2005; 561–3. doI: 10.1515/JPM.2005.100
30. Смирнов А.В., Бологов А.А., Брюсова И.Б., Волкова Г.И., Ильина Е.С. Применение Октагама при тяжелых инфекционных заболеваниях у детей. Детские инфекции. 2003; 40–4. [Smirnov A.V., Bologov A.A., Bryusova I.B., Volkova G.I., Ilyina E.S. The use of Octagam in severe infectious diseases in children. Children’s infections. 2003; 40–4. (in Russian)].
31. Society for Maternal-Fetal Med Fetal blood sampling. Am J Obstet Gynecol. 2013; 5: 170–80. doi: 10.1016/j.ajog.2013.07.014
32. Беспалова Е.Д., Бокерия Е.Л. Перинатальный кардиологический скрининг - методические рекомендации для врачей неонатологов, педиатров, акушеров-гинекологов, врачей функциональной диагностики. Вопросы практической педиатрии. 2010; 5 (1): 60–2. [Bespalova E.D., Bokeria E.L. Perinatal cardiological screening - guidelines for neonatologists, pediatricians, obstetrician-gynecologists, doctors of functional diagnostics. Questions of practical pediatrics. 2010; 5 (1): 60–2. (in Russian)].

Received 27.11.2019

Accepted 29.11.2019